Laurion Capital Management LP Biocryst Pharmaceuticals Inc Transaction History

Laurion Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$4.13 - $6.79 $108,280 - $178,020	26,218 Added 21.41%	148,655 $918,000
Q1 2024 May 15, 2024	SELL	$4.89 - $7.65 $55,442 - $86,735	-11,338 Reduced 8.48%	122,437 $621,000
Q4 2023 Feb 14, 2024	BUY	$4.98 - $6.77 $666,199 - $905,656	133,775 New	133,775 $801,000
Q4 2017 Feb 13, 2018	SELL	$4.16 - $5.33 $899,233 - $1.15 Million	-216,162 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$4.1 - $5.97 $886,264 - $1.29 Million	216,162	216,162 $1.13 Million

278

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.